The enhanced ERK1/2 activation in RAF-wild-type cells means that ∼20% of patients treated with vemurafenib or dabrafenib develop non-metastatic skin tumours [85,86], pre-malignant colonic adenomas and gastric polyps after RAF inhibitor treatment [87]. Here, RAF1 is linked to colon adenoma.